GlobeNewswire·Nov 10, 2026, 4:05 PM ET

Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

Longer-term follow-up data from the Phase 1 CARLYSLE trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE) were presented at ACR Convergence 2026.
As of August 11, 2026, 15 patients (8 adults 50M dose, 3 adolescents 50M dose, 4 adults 100M dose) received obe-cel infusions.
Median follow-up periods were 19.0 months for adult 50M, 12.4 months for adult 100M, 10.1 months for adolescent 50M, with a maximum of 25.5 months.
Clinically significant improvements in SLEDAI-2K scores were observed in most patients, along with achievement of DORIS criteria despite severe baseline disease activity.
All patients followed for at least six months achieved DORIS response criteria.
Complete renal response (CRR) was achieved in 6 of 9 participants (66.7%) with active lupus nephritis, while 1 participant (11.1%) achieved partial renal response at Month 7.
No severe renal flares were observed during the study period.
The therapy demonstrated a favorable safety profile with no ICANS, HLH/IEC-HS, or Grade ≥3 CRS events in 15 evaluable patients.
Robust CAR T-cell expansion 4 deep B-cell depletion occurred post-infusion, followed by B-cell reconstitution with predominantly transitional/naïve phenotypes.
Median B-cell recovery times were 7.2 months (50M adult), 4.3 months (100M adult), 4.3 months (100M adult), 6.0 months (50M adolescent).
Obe-cel is currently being evaluated in the Phase II LUMINA trial for srSLE with active lupus nephritis using a single flat dose of 50M.

Company: Autolus Inc.
Keywords: Nasdaq:AUTL, Autolus Inc., SLE, carlysle trial, systemic lupus erythematosus, lupus nephritis, obe-cel, Dr Matthias Will